Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 16/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16634118 | 0.85 | PDE2A (0.48) | PDE2AEPHX2 | |
| SCHEMBL16633541 | 0.85 | PDE2A (0.48) | PDE2AEPHX2 | |
| SCHEMBL16633441 | 0.84 | PDE2A (0.47) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16633314 | 0.83 | PDE2A (0.53) | PDE2AEPHX2SLC7A5TRPM8 | |
| SCHEMBL16632995 | 0.82 | EPHX1 (0.41) | EPHX2 | |
| SCHEMBL16633010 | 0.79 | PDE2A (0.57) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16633655 | 0.77 | PDE2A (0.49) | PDE2AEPHX2TRPM8 | |
| SCHEMBL16564005 | 0.74 | PDE2A (0.49) | PDE2AEPHX2TRPM8 | |
| SCHEMBL19946337 | 0.74 | PDE2A (0.50) | PDE2AEPHX2SLC7A5TRPM8 | |
| SCHEMBL6324272 | 0.74 | CYP2C19 (0.42) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | PDE2A 1/4885EPHX2 1190/4885SLC7A5 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.